Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash from Financing Activities (2020 - 2023)

Historic Cash from Financing Activities for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$121000.0.

  • Candel Therapeutics' Cash from Financing Activities fell 43611.11% to -$121000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$121000.0, marking a year-over-year decrease of 10060.58%. This contributed to the annual value of $94.3 million for FY2024, which is 7801735.54% up from last year.
  • According to the latest figures from Q4 2023, Candel Therapeutics' Cash from Financing Activities is -$121000.0, which was down 43611.11% from $36000.0 recorded in Q4 2022.
  • Candel Therapeutics' 5-year Cash from Financing Activities high stood at $71.4 million for Q3 2021, and its period low was -$121000.0 during Q4 2023.
  • Over the past 4 years, Candel Therapeutics' median Cash from Financing Activities value was $74000.0 (recorded in 2021), while the average stood at $11.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 1768214.29% in 2022, then plummeted by 43611.11% in 2023.
  • Candel Therapeutics' Cash from Financing Activities (Quarter) stood at $29000.0 in 2020, then skyrocketed by 245951.72% to $71.4 million in 2021, then tumbled by 99.95% to $36000.0 in 2022, then crashed by 436.11% to -$121000.0 in 2023.
  • Its Cash from Financing Activities was -$121000.0 in Q4 2023, compared to $36000.0 in Q4 2022 and $22000.0 in Q2 2022.